Literature DB >> 14671086

Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Inna G Ovsyannikova1, Kenneth L Johnson, David C Muddiman, Robert A Vierkant, Gregory A Poland.   

Abstract

Previously, we identified a naturally processed and presented measles virus (MV) 19-amino-acid peptide, ASDVETAEGGEIHELLRLQ (MV-P), derived from the phosphoprotein and eluted from the human leukocyte antigen (HLA) class II molecule by using mass spectrometry. We report here the identification of a 14-amino-acid peptide, SAGKVSSTLASELG, derived from the MV nucleoprotein (MV-N) bound to HLA-DRB1*0301. Peripheral blood mononuclear cells (PBMC) from 281 previously vaccinated measles-mumps-rubella II (MMR-II) subjects (HLA discordant) were studied for peptide recognition by T cells. Significant gamma interferon (IFN-gamma) responses to MV-P and MV-N peptides were observed in 55.9 and 15.3% of subjects, respectively. MV-P- and MV-N-specific interleukin-4 (IL-4) responses were detected in 19.2 and 23.1%, respectively, of PBMC samples. Peptide-specific cytokine responses and HLA-DRB1 allele associations revealed that, for the MV-P peptide, the allele with the strongest association with both IFN-gamma (P = 0.02) and IL-4 (P = 0.03) secretion was DRB1*0301. For MV-N, the allele with the strongest association with IFN-gamma secretion was DRB1*1501 (P = 0.04), and the alleles with the strongest associations with IL-4 secretion were DRB1*1103 and DRB1*1303 (P = 0.01). These results indicate that HLA class II MV proteins can be processed, presented, and identified, and the ability to generate cell-mediated immune responses can be demonstrated. This information is promising for new vaccine design strategies with peptide-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14671086      PMCID: PMC303425          DOI: 10.1128/jvi.78.1.42-51.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles.

Authors:  D L Doolan; S Southwood; R Chesnut; E Appella; E Gomez; A Richards; Y I Higashimoto; A Maewal; J Sidney; R A Gramzinski; C Mason; D Koech; S L Hoffman; A Sette
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 2.  Successes and failures in measles control.

Authors:  F T Cutts; L E Markowitz
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

3.  Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies.

Authors:  K C El Kasmi; S Fillon; D M Theisen; H Hartter; N H Brons; C P Muller
Journal:  J Gen Virol       Date:  2000-03       Impact factor: 3.891

4.  A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains.

Authors:  C A van Els; C A Herberts; E van der Heeft; M C Poelen; J A van Gaans-van den Brink; A van der Kooi; P Hoogerhout; G Jan ten Hove; H D Meiring; A P de Jong
Journal:  Eur J Immunol       Date:  2000-04       Impact factor: 5.532

5.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; Stephen Naylor; David C Muddiman; Gregory A Poland
Journal:  Virology       Date:  2003-08-01       Impact factor: 3.616

Review 7.  Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons.

Authors:  G A Poland; R M Jacobson
Journal:  Arch Intern Med       Date:  1994-08-22

8.  Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus.

Authors:  O E Obeid; C D Partidos; C R Howard; M W Steward
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis.

Authors:  D Finke; U G Brinckmann; V ter Meulen; U G Liebert
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles.

Authors:  D A Kirschmann; K L Duffin; C E Smith; J K Welply; S C Howard; B D Schwartz; S L Woulfe
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

View more
  18 in total

1.  Consistency of HLA associations between two independent measles vaccine cohorts: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-25       Impact factor: 3.641

2.  HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Steven J Jacobsen; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-01-27       Impact factor: 2.846

Review 3.  Vaccinomics: current findings, challenges and novel approaches for vaccine development.

Authors:  Inna G Ovsyannikova; Gregory A Poland
Journal:  AAPS J       Date:  2011-06-14       Impact factor: 4.009

4.  Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus.

Authors:  Kenneth L Johnson; Inna G Ovsyannikova; Benjamin J Madden; Gregory A Poland; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-26       Impact factor: 3.109

5.  Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-26       Impact factor: 3.641

Review 6.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

Review 7.  Personalized vaccines: the emerging field of vaccinomics.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

8.  Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.

Authors:  Kenneth L Johnson; Inna G Ovsyannikova; Christopher J Mason; H Robert Bergen; Gregory A Poland
Journal:  Vaccine       Date:  2009-10-12       Impact factor: 3.641

Review 9.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

Review 10.  Variability in Humoral Immunity to Measles Vaccine: New Developments.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Jennifer A Whitaker; Gregory A Poland
Journal:  Trends Mol Med       Date:  2015-11-18       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.